Plus Therapeutics
PSTV
PSTV was delisted on the 31st of July, 2026.
20 hedge funds and large institutions have $3.57M invested in Plus Therapeutics in 2025 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 8 closing their positions.
2,610% more capital invested
Capital invested by funds: $132K → $3.57M (+$3.43M)
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
11% more funds holding
Funds holding: 18 → 20 (+2)
0.18% more ownership
Funds ownership: 0.03% → 0.21% (+0.18%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$695K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$374K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$263K |
| 4 |
BlackRock
New York
|
+$227K |
| 5 |
State Street
Boston,
Massachusetts
|
+$168K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$40.9K |
| 2 |
Goldman Sachs
New York
|
-$9.3K |
| 3 |
Millennium Management
New York
|
-$8.43K |
| 4 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
-$3.98K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.24K |
PSTV Hedge Fund Activity: Q3 2025 in Review
20 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q3 2025, worth a combined $3.57M — up 2,610% from $132K a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new PSTV positions and 8 closed out — a net gain of 2 holders — while 7 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, adding an estimated $695K. The largest seller was Jane Street, exiting entirely with an estimated $40.9K sold.
- 20 institutional investors held Plus Therapeutics (PSTV) as of Q3 2025, up from 18 in Q2 2025.
- Funds reported $3.57M of Plus Therapeutics stock for Q3 2025, up 2,610% quarter-over-quarter.
- 10 funds opened new Plus Therapeutics positions in Q3 2025 and 8 closed out, a net change of +2 holders.
- The largest Plus Therapeutics buyer in Q3 2025 was Vanguard Group, an estimated $695K added.
- The largest Plus Therapeutics seller in Q3 2025 was Jane Street, an estimated $40.9K sold.
Based on aggregated 13F filings for Q3 2025.